Navigation Links
Amira Pharmaceuticals to Present Preclinical Data on AM152 , an LPA1 Receptor Antagonist, at the Annual Meeting of the American Thoracic Society
Date:5/11/2011

SAN DIEGO, May 11, 2011 /PRNewswire/ -- Amira Pharmaceuticals, Inc. announced today that it will present preclinical data on AM152, an LPA1 receptor antagonist, during the Annual Meeting of the American Thoracic Society (ATS) in Denver, Colorado.  The poster, titled "The LPA1 Antagonist, AM152, Is Efficacious in Mouse Models of Fibrosis," will be presented on Monday, May 16, from 8:15 to 10:45 a.m. MDT.

The LPA1 receptor is part of the lysophosphatidic acid signaling pathway.  Under pathological conditions, LPA1 is associated with a breakdown of the endothelial barrier and the stimulation of fibroblast recruitment, proliferation and transformation, resulting in excessive deposition of extracellular matrix proteins.  Studies have shown that the LPA1 receptor may play a role in several fibrotic diseases, including Idiopathic Pulmonary Fibrosis (IPF).

"Our preclinical data demonstrate that AM152 reduces pro-fibrotic activity by fibroblasts in vitro and tissue fibrosis in numerous in vivo models," said Gretchen Bain, Ph.D., Executive Director of Biology.  "AM152 reduces fibrosis in multiple tissue types thus providing a strong rationale for clinical exploration in patients suffering from a variety of fibrotic diseases."

Bob Baltera, Chief Executive Officer, added, "Our lead LPA1 program, AM152, is one of the cornerstones for Amira's future.  As previously disclosed, we look forward to initiating Phase 2a clinical studies in patients suffering from fibrotic disease in order to explore the therapeutic benefit of this compound."

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases.  Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient development of novel compounds and effective pre-clinical and clinical program decisions.  Our team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and various fibrotic diseases.  Amira has a partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase activating protein) inhibitors in respiratory and cardiovascular disease.  For more information, visit www.amirapharm.com.

Media Contact
Ian Stone
Russo Partners
Tel: +1 619 528 2220
ian.stone@russopartnersllc.com


'/>"/>
SOURCE Amira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amira Pharmaceuticals Announces Completion of Phase 1 Clinical Study for AM152, A Novel LPA1 Receptor Antagonist
2. Amira Pharmaceuticals Receives Orphan Drug Status for a Novel LPA1 Antagonist, AM152, for the Treatment of Idiopathic Pulmonary Fibrosis
3. Amira Pharmaceuticals Announces the Nomination of an Orally Available Pre-Clinical Candidate in a New LPA-Related Program, an Autotaxin Inhibitor
4. Amira Pharmaceuticals Announces Initiation of Phase I Clinical Trial for AM152, A Novel LPA1 Antagonist
5. Amira Pharmaceuticals Announces IND Submission for Novel LPA1 Antagonist, AM152, for Potential Use in Fibrotic Diseases
6. Amira Pharmaceuticals Named One of Most Promising Biotech Companies by FierceBiotechs Annual Fierce 15
7. Visage Imaging Releases Amira 5.3
8. Amira Announces AM103 and AM803 Patent Grant in the United Kingdom
9. Amira Announces Second DP2 Antagonist Patent Grant in the United Kingdom
10. Anti-Fibrotic Data from Amira Pharmaceuticals LPA1 Receptor Antagonist Program Published in the British Journal of Pharmacology
11. Amira Pharmaceuticals Announces Efficacy of LPA1 Antagonist in a Preclinical Model of Scleroderma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... Research Future published a Half Cooked Research Report on Endoscopy Devices ... 33.6 million during the period 2016 to 2022 from USD 28.7 ... ... examined as a swiftly growing market and expected to grow at ... in various regions.  The increasing growth in endoscopy procedures is influencing ...
(Date:1/17/2017)... KANSAS CITY, Mo. , Jan. ... (CHNC) has selected Velos and its flagship technology ... and multicenter initiatives. CHNC is a ... Neonatal Intensive Care Units at leading children,s hospitals ... consortium provides a benchmark of care and short-term ...
(Date:1/17/2017)...  Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is ... Inc. ("Anthera" or the "Company") (NASDAQ: ANTH ). ... the investigation by visiting the firm,s site: www.bgandg.com/anth .   ... its officers and/or directors have violated Sections 10(b) and 20(a) ... ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... January 17, 2017 , ... Etymotic Research will ... of Music Merchants (NAMM) winter trade show, Booth #2876, at the Anaheim Convention ... long been the gold standard for high-definition, in-ear earphones. This classic earphone has ...
(Date:1/17/2017)... ... 17, 2017 , ... Mirror Mirror Beauty Boutique, Houston’s premiere CoolSculpting provider ... in Zeltiq’s Crystal Rewards Program. Practice founder, Paul Vitenas, MD FACS, is delighted that ... , Produced by Zeltiq, CoolSculpting is approved by the Food and Drug Administration ...
(Date:1/17/2017)... ... January 17, 2017 , ... Surgeons ... to primary eye care practitioners on the latest breakthroughs in the prevention, diagnosis ... Continuing Education Symposium, according to eye surgeon, Jeffrey Martin, MD, FACS, Chief Executive ...
(Date:1/17/2017)... ... 17, 2017 , ... Neil H. Greco Insurance Agency, a northern New Jersey ... region, is launching a charity drive to raise awareness of heart disease and promote ... in America, and is responsible for 1 in every 4 deaths at the national ...
(Date:1/17/2017)... ... January 17, 2017 , ... Livionex, Inc., a Silicon Valley ... double blind clinical study for its dental gel that shows significant reduction in plaque ... toothpaste containing triclosan. The study was conducted at the Beckman Laser Institute at UC ...
Breaking Medicine News(10 mins):